Add us as a preferred source
The latest investment rounds and corporate developments in digital health and life sciences, including a psychiatry operating system, a SPAD-based image sensor startup, and diagnistictechnology.
Singular Photonics lands $2.2 million seed funding
University of Edinburgh spinout Singular Photonics has closed an oversubscribed $2.15 million (£1.6 million) seed funding round led by ACF Investors. The financing saw participation from Wren Capital, Cambridge Angels, Scottish Enterprise, Quantum Exponential and Old College Capital.
Spun out of the University of Edinburgh’s School of Engineering, the startup develops image sensors based on single-photon avalanche diode (SPAD) technology. Unlike conventional image sensors that record aggregate light intensity, SPAD sensors detect and time individual photons. By integrating on-chip digital computation at the pixel level, Singular Photonics’ platform processes data at the point of light detection, enabling real-time edge computing for medical imaging, scientific discovery, machine vision, industrial automation and physical AI systems.
The startup will use the capital to scale its engineering capacity and accelerate the commercial rollout of its next-generation imager portfolio. Commercial traction has accelerated this year, with the business doubling revenue to date on last year and approaching break-even. Growth has been driven by expanding customer engagements, including a strategic collaboration with precision instrumentation group Renishaw to integrate SPAD sensors into time-resolved Raman spectroscopy systems. Alongside the funding, Singular Photonics appointed Dipesh Patel, former chief technology officer of semiconductor giant Arm, to its board of directors.
“We’ve already doubled our 2025 sales, we’re approaching break-even, and our customers are telling us exactly what they want from future products,” said Singular Photonics chief executive Shahida Imani. “This oversubscribed round means we can respond faster – expanding our sensor portfolio and bringing new features to market on our customers’ timelines, not just our own.”
Aisel Health raises €1.7 million pre-seed round
Copenhagen-based healthtech startup Aisel Health has raised €1.7 million (£1.4 million) pre-seed funding to fund its expansion into the UK market. The financing was led by Caesar Ventures, with participation from Nordic Web Ventures, LifeX, Angel Invest, and returning investors Rockstart and EIFO.
The company will use the fresh capital to expand its clinical and engineering teams and fund its entry into the UK, where it is converting an active commercial pipeline of private psychiatry clinics ahead of a planned seed round.
Co-founded in 2024 by chief executive Augusta Klingsten Peytz and chief product officer Christian Houen, Aisel Health develops a clinical operating system purpose-built for psychiatric care.
While first-generation AI note-taking tools have focused on speeding up consultation transcription, the resulting volume of clinical notes has created a downstream information retrieval bottleneck across disparate electronic health systems. Aisel Health’s platform resolves this by aggregating intake forms, historical notes, referral letters and real-time interview recordings into structured, contextual insights before, during and after consultations. By surfacing critical longitudinal patient history at the point of care, the technology wants to reduce administrative burdens and shorten patient waiting lists.
“Psychiatry doesn’t need more generic technology bolted onto an already overburdened workflow,” said Augusta Klingsten Peytz, co-founder and chief executive of Aisel Health. “It needs a product built around the realities of psychiatric care – where clinicians bring judgment, empathy, and years of trained intuition, and the technology brings the speed, structure and ability to hold together every detail about every patient, in a way no human memory can.”
Trinity Biotech raises $7 million funding
Dublin-headquartered diagnostics company Trinity Biotech has secured $7 million (£5.4 million) in additional financing from life sciences investor Perceptive Advisors, its primary lender and largest institutional shareholder. The total commitment is made up of $2.5 million in new debt funding alongside $4.5 million in capitalised interest under an amendment to the group’s existing credit facility.
The cash injection strengthens Trinity Biotech’s balance sheet as the company repositions itself towards next-generation diagnostic technologies and digital healthcare solutions. Capital will support strategic growth initiatives, including the clinical advancement of its CGM+ wearable continuous glucose monitoring biosensor platform, ongoing diagnostics commercialisation, and expansion into liquid cooling solutions for AI data centre infrastructure via its Trinovium subsidiary.
Alongside the funding, Trinity Biotech says that it has regained compliance with Nasdaq’s minimum bid price requirement. The company’s American Depositary Shares (ADSs) maintained a closing bid price of at least $1.00 per share for ten consecutive business days between 24 July and 6 August, satisfying listing rules. Preliminary revenues for the quarter ending in June, reached approximately $10.5 million, tracking broadly flat against the first quarter of the year as management focuses on completing its corporate transformation.
“Perceptive’s additional investment and the restoration of our compliance with Nasdaq’s minimum bid price requirement represent important positive developments for Trinity Biotech,” said chief executive John Gillard. “We believe this further investment reflects confidence in the strategic direction of the company and the exciting opportunities ahead of us.”
